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monitoring. In reality however, a signiﬁcant number of healthcare
providers (HCPs) do not have good HIV care experiences while
having serious service workload, prescribing ARVs without proper
laboratory monitoring may lead to more proportion of patients
with virological failure and HIV drug resistance. For RLS, it is
therefore important to implement some proper and cost-effective
monitoring strategies while operating earlier ART policy.
Inprinciples, goodHCP-patient relationship toensure treatment
adherence is “the must do” and the most cost-effective measure.
Each RLS should consider a minimal set of laboratory tests to be
included in their services such as CBC, creatinine (before initiating
TDF) for safety; TB screening and VDRL for co-infection screening.
In case of ART efﬁcacy, CD4 at baseline then 2 times a year until
CD4>350; and as long as VL is well suppressed, we may not need
further testing. WHO 2013 has recommended to perform VL test, if
available it should be tested every 6 months until becoming unde-
tectable then once a-year. There are more low cost (<3 USD/test)
and point-of-care (POC) CD4 tests available commercially. Low cost
POC VL-test is not yet available. Current low cost VL test in some
RLS is based on a homebrew real-time PCR assay (cost < 5USD/test).
However, it requires expensive equipments and experience tech-
nicians to run the service. While POC VL tests in not yet available,
HIV care system in RLS may consider setting up few central labs
to provide low cost homebrew VL test and validate the dried-
blood spot sample testing systems. Nonetheless, in settings where
resources are truly constraint, it should not prevent from imple-
menting ART for HIV symptomatic patients or thosewith CD4<350
if someessential labmonitoring isnot available.Allmeans toensure
adherence is warranted.
http://dx.doi.org/10.1016/j.ijid.2014.03.477
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Antiretroviral therapy (ART) for HIV infection decreases HIV
RNA levels, increases CD4 cell counts and general immune func-
tion, prevents clinical progression, and prolongs survival. Despite
these clear beneﬁts, the optimal time of initiation of ART remains
uncertain. ART treatment guidelines worldwide agree in the rec-
ommendation to start ART in anyHIV-infected patientwith AIDS or
symptomatic HIV disease. Despite concerns about drug toxicities,
drug interactions, and the immune reconstitution syndrome, start-
ing ART earlier during an acute opportunistic infection (including
tuberculosis) clearlywasassociatedwithclinical beneﬁts, including
prolonged survival, in randomized clinical studies.More controver-
sial is the timing of starting ART during an acute central nervous
system opportunistic infection such as cryptococcosis or tuber-
culosis with some randomized clinical studies suggesting earlier
ART was associated with increased mortality. ART guidelines dif-
fer in their recommendations for starting ART in asymptomatic
patients. Some guidelines base their recommendations for start-
ing ART on speciﬁc CD4 cell count thresholds and/or the presence
of any of a number of co-morbidities such as hepatitis B, hep-
atitis C, non-AIDS malignancies requiring treatment, idiopathic
thrombocytopenic purpura (ITP), increased cardiovascular risk,
neurocognitive changes, renal disease including HIV-associated
nephropathy (HIVAN), and active or latent tuberculosis. Despite
the disagreement in treatment guidelines about the optimal time
to start ART in asymptomatic patients, there is a clear trend for
starting ART earlier in HIV infection. For example, World Health
Organization (WHO) treatment guidelines have increased CD4
cell count thresholds for starting ART from 200/uL to 350/uL
to 500/uL in recent years. Part of the rationale for starting ART
earlier is to avoid non-AIDS comorbidities that may be associ-
ated with the inﬂammation and immune activation associated
with untreated HIV infection, including cardiovascular, renal,
liver, neurologic, andmalignant diseases. Additional observational,
interventional, and randomized clinical studies are in progress
and will help inform the important decision of when to start
ART.
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The number of people living with HIV accessing antiretroviral
treatment in resource-limited countries has increased from a few
thousands pre-2000 to almost 10million in 2013. This achievement
is unprecedented in the history of public health and has resulted in
important decreases in HIV-related mortality, including a 10 year
increase in life expectancy in South Africa. Yet, this scale up is not
without problems. Retention in care is poor, data on virological
success rates is scarce, signiﬁcant numbers of patients are seek-
ing health carewith advanced immunosuppression, and increasing
medicine stock outs are symptomatic of the limits of existinghealth
systems. According to the latest WHO guidelines, another 16 mil-
lion people are in need of ART,most ofwhomdonot know their HIV
status. This presentation examines the factors contributing to the
success of the ART scale up, the challenges it faces, and strategies
to scale up further whilst maintaining quality of care.
This presentation examines the factors contributing to the suc-
cess of the ART scale up, the challenges it faces, and strategies to
scale up further whilst maintaining quality of care.
A number of critical historical factors have made this success
possible: strong activist movements in rich and poor countries,
massive increases in vertical funding, the Doha declaration on
TRIPS agreement and public health, generic competition resulting
in prices of ﬁrst line ART decrease from over 10,000 USD to less
than 100 USD per patient per year, programmatic innovations and
paradigm shifts in public health and political will. Yet the success
is unequally distributed and access to ART remains low in many
countries (such as most of central and west Africa) and popula-
tions (e.g. intravenous drug users). Challenges include losses along
the test to treatment cascade, treatment failure, pediatric and ado-
lescentHIV,medicine stock outs, overburdenedhealth systems and
